Myasthenia gravis is an autoimmune neuromuscular disease where antibodies block acetylcholine receptors at the nerve-muscle junction, causing fluctuating muscle weakness that worsens with activity. It can range from mild eye involvement to respiratory crisis requiring ventilator support.
What's actually going on in research
FcRn inhibitors that accelerate the clearance of pathogenic antibodies from the blood — including efgartigimod and rozanolixizumab — are producing rapid improvement in generalized MG. Complement inhibitors like eculizumab and ravulizumab are now standard for severe generalized MG. Trials are testing these new mechanisms in thymoma-associated and seronegative MG, and early intervention to prevent crisis is being studied.
FcRn inhibitors
Drugs like efgartigimod reduce circulating AChR and MuSK antibody levels rapidly by blocking the receptor that recycles antibodies in the body, producing fast improvement in MG weakness.
Complement inhibitors
Eculizumab and ravulizumab block complement activation at the neuromuscular junction, reducing destruction of acetylcholine receptors. Trials are extending their use to earlier and milder disease.
B-cell depletion
Rituximab depletes antibody-producing B-cells in MG and is being tested in newly diagnosed generalized MG to achieve early remission and reduce long-term corticosteroid dependence.
What to know before you search
Eligibility depends on MG subtype (AChR-antibody positive vs. MuSK vs. seronegative), disease generalization, MGFA severity class, and prior immunosuppression.
What types of trials are currently open
- FcRn inhibitor trials — Testing efgartigimod, rozanolixizumab, and nipocalimab for rapid antibody clearance in generalized MG.
- Complement inhibitor trials — Evaluating eculizumab, ravulizumab, and newer complement drugs across MG subtypes.
- B-cell depletion trials — Testing rituximab as early-line therapy to achieve sustained remission in generalized MG.
- Thymectomy trials — Evaluating surgical thymectomy outcomes in non-thymomatous generalized MG.
- Seronegative MG trials — Testing treatments specifically for MuSK-positive and double-seronegative myasthenia gravis.
Recently added Myasthenia Gravis trials
Track your neuroimmune disease health during pregnancy over five years
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility. Therefore, effective management of neuroimmune diseases during pregnancy is particularly important. This study included a follow-up period of up to five years in patients with pregnancy-associated neuroimmune disorders. Data collected included relapse frequency, symptomatology, imaging findings, treatment regimens, peripheral blood profiles, EDSS scores, and MRI results. In addition, maternal drug concentrations, postpartum relapse rates, and neonatal development were monitored after delivery. Following the successful completion of the five-year follow-up, the research team plans to continue the prospective epidemiological study with ten-year follow-up phases. The aim of this study is to generate detailed clinical data on pregnancy-associated autoimmune diseases and to equip clinicians with evidence-based strategies for optimizing disease management during the reproductive age.
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Find Myasthenia Gravis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.